| |
Whole cohort (a)
|
DM subgroup (b)
|
|---|
|
Univariate
|
Multivariate
|
Univariate
|
|---|
| |
HR
|
95.0% CI
|
P
|
HR
|
95.0% CI
|
P
|
HR
|
95.0% CI
|
P
|
|---|
|
Age
|
0.86
|
0.59
|
–
|
1.25
|
0.415
| | | | | |
0.94
|
0.84
|
–
|
1.06
|
0.306
|
|
Sex
|
1.94
|
1.14
|
–
|
3.30
|
0.014*
|
1.66
|
0.71
|
–
|
3.88
|
0.245
|
4.13
|
0.98
|
–
|
17.44
|
0.054
|
|
Smoking
|
1.34
|
0.91
|
–
|
1.96
|
0.136
|
0.84
|
0.46
|
–
|
1.52
|
0.558
|
3.438
|
0.311
|
–
|
38.06
|
0.314
|
|
BMI > 24 kg/m2
|
1.1
|
0.75
|
–
|
1.62
|
0.610
| | | | | |
1.61
|
0.65
|
–
|
3.98
|
0.301
|
|
Hypertension
|
0.74
|
0.51
|
–
|
1.08
|
0.113
|
1.12
|
0.60
|
–
|
2.06
|
0.726
|
0.67
|
0.25
|
–
|
1.77
|
0.418
|
|
Cre > 1.5 mg/dL
|
1.03
|
0.60
|
–
|
1.77
|
0.921
| | | | | |
1.04
|
0.42
|
–
|
2.56
|
0.936
|
|
Dialysis
|
0.88
|
0.28
|
–
|
2.78
|
0.831
| | | | | |
1.57
|
0.21
|
–
|
11.7
|
0.658
|
|
History of other cancers
|
0.71
|
0.36
|
–
|
1.41
|
0.335
| | | | | |
0.63
|
0.15
|
–
|
2.69
|
0.536
|
|
cT1
|
2.14
|
1.47
|
–
|
3.12
|
< 0.001*
|
2.05
|
1.06
|
–
|
3.97
|
0.034*
|
1.83
|
0.87
|
–
|
3.86
|
0.112
|
|
CIS
|
1.58
|
1.03
|
–
|
2.41
|
0.036*
|
0.69
|
0.34
|
–
|
1.39
|
0.297
|
1.34
|
0.6
|
–
|
2.96
|
0.476
|
|
High grade
|
1.72
|
1.14
|
–
|
2.58
|
0.010*
|
0.85
|
0.43
|
–
|
1.68
|
0.643
|
1.45
|
0.61
|
–
|
3.42
|
0.400
|
|
Tumor number ≥ 3
|
2.49
|
1.58
|
–
|
3.94
|
< 0.001*
|
3.46
|
1.90
|
–
|
6.33
|
< 0.001*
|
0.99
|
0.41
|
–
|
2.41
|
0.982
|
|
Tumor size ≥3 cm
|
1.94
|
1.12
|
–
|
3.36
|
0.018*
|
1.90
|
1.05
|
–
|
3.42
|
0.033*
|
1.94
|
0.64
|
–
|
5.83
|
0.239
|
|
Intravesical therapy
|
0.97
|
0.36
|
–
|
2.64
|
0.958
| | | | | |
21.8
|
< 0.01
|
–
|
> 11.00
|
0.790
|
|
DM
|
1.3
|
0.85
|
–
|
2.00
|
0.229
|
1.11
|
0.57
|
–
|
2.19
|
0.755
| | | | | |
|
Urine sugar ≥100
| | | | | | | | | | |
1.86
|
0.87
|
–
|
3.97
|
0.108
|
|
HbA1c ≥7
| | | | | | | | | | |
3.64
|
1.14
|
–
|
11.65
|
0.029*
|
|
Metformin
| | | | | | | | | | |
1.36
|
0.60
|
–
|
3.10
|
0.460
|
|
TZD
| | | | | | | | | | |
0.26
|
0.04
|
–
|
1.90
|
0.184
|
- a. Whole cohort: Male sex, T1 stage, CIS, high grade, tumor number ≥ 3, and tumor size ≥3 were associated with higher recurrence in univariate analysis. T1 stage, tumor number ≥ 3, and tumor size ≥3 were independent risk factors for recurrence in multivariate analysis
- b. DM subgroup: HbA1c ≥7 was associated with higher risk of recurrence
- CI confidence interval, CIS carcinoma in situ, DM diabetes mellitus; HR hazard ratio, RFS recurrence-free survival, TZDs thiazolidinedione; * P < 0.05
